109 related articles for article (PubMed ID: 12533760)
1. Conjugates of aberrant gangliosides in antiglioma vaccine: toxicological assay.
Lombardi V; Shnaar R; Minev B; Misasi R; Gitstsi Kh; Sorice M; Troncone A
Bull Exp Biol Med; 2002 Oct; 134(4):363-5. PubMed ID: 12533760
[TBL] [Abstract][Full Text] [Related]
2. A preclinical study comparing approaches for augmenting the immunogenicity of a heptavalent KLH-conjugate vaccine against epithelial cancers.
Ragupathi G; Koide F; Sathyan N; Kagan E; Spassova M; Bornmann W; Gregor P; Reis CA; Clausen H; Danishefsky SJ; Livingston PO
Cancer Immunol Immunother; 2003 Oct; 52(10):608-16. PubMed ID: 12811527
[TBL] [Abstract][Full Text] [Related]
3. Comparison of antibody titers after immunization with monovalent or tetravalent KLH conjugate vaccines.
Ragupathi G; Cappello S; Yi SS; Canter D; Spassova M; Bornmann WG; Danishefsky SJ; Livingston PO
Vaccine; 2002 Jan; 20(7-8):1030-8. PubMed ID: 11803062
[TBL] [Abstract][Full Text] [Related]
4. Keyhole limpet hemocyanin conjugate vaccines against cancer: the Memorial Sloan Kettering experience.
Musselli C; Livingston PO; Ragupathi G
J Cancer Res Clin Oncol; 2001 Oct; 127 Suppl 2():R20-6. PubMed ID: 11768620
[TBL] [Abstract][Full Text] [Related]
5. Bioengineering of surface GD3 ganglioside for immunotargeting human melanoma cells.
Zou W; Borrelli S; Gilbert M; Liu T; Pon RA; Jennings HJ
J Biol Chem; 2004 Jun; 279(24):25390-9. PubMed ID: 15047693
[TBL] [Abstract][Full Text] [Related]
6. Effect of immunological adjuvant combinations on the antibody and T-cell response to vaccination with MUC1-KLH and GD3-KLH conjugates.
Kim SK; Ragupathi G; Cappello S; Kagan E; Livingston PO
Vaccine; 2000 Oct; 19(4-5):530-7. PubMed ID: 11027818
[TBL] [Abstract][Full Text] [Related]
7. GD3 vaccines for melanoma: superior immunogenicity of keyhole limpet hemocyanin conjugate vaccines.
Helling F; Shang A; Calves M; Zhang S; Ren S; Yu RK; Oettgen HF; Livingston PO
Cancer Res; 1994 Jan; 54(1):197-203. PubMed ID: 8261439
[TBL] [Abstract][Full Text] [Related]
8. Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-21.
Ragupathi G; Livingston PO; Hood C; Gathuru J; Krown SE; Chapman PB; Wolchok JD; Williams LJ; Oldfield RC; Hwu WJ
Clin Cancer Res; 2003 Nov; 9(14):5214-20. PubMed ID: 14614001
[TBL] [Abstract][Full Text] [Related]
9. Keyhole limpet hemocyanin (KLH) conjugate vaccines as novel therapeutic tools in malignant disorders.
Schumacher K
J Cancer Res Clin Oncol; 2001 Oct; 127 Suppl 2():R1-2. PubMed ID: 11768617
[No Abstract] [Full Text] [Related]
10. Prospects for total synthesis: a vision for a totally synthetic vaccine targeting epithelial tumors.
Keding SJ; Danishefsky SJ
Proc Natl Acad Sci U S A; 2004 Aug; 101(33):11937-42. PubMed ID: 15280546
[TBL] [Abstract][Full Text] [Related]
11. Fully synthetic carbohydrate-based vaccines in biochemically relapsed prostate cancer: clinical trial results with alpha-N-acetylgalactosamine-O-serine/threonine conjugate vaccine.
Slovin SF; Ragupathi G; Musselli C; Olkiewicz K; Verbel D; Kuduk SD; Schwarz JB; Sames D; Danishefsky S; Livingston PO; Scher HI
J Clin Oncol; 2003 Dec; 21(23):4292-8. PubMed ID: 14645418
[TBL] [Abstract][Full Text] [Related]
12. Specific immunization using keyhole limpet hemocyanin-ganglioside conjugates.
Jennemann R; Gnewuch C; Bosslet S; Bauer BL; Wiegandt H
J Biochem; 1994 Jun; 115(6):1047-52. PubMed ID: 7982880
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity of a fucosyl-GM1-keyhole limpet hemocyanin conjugate vaccine in patients with small cell lung cancer.
Dickler MN; Ragupathi G; Liu NX; Musselli C; Martino DJ; Miller VA; Kris MG; Brezicka FT; Livingston PO; Grant SC
Clin Cancer Res; 1999 Oct; 5(10):2773-9. PubMed ID: 10537341
[TBL] [Abstract][Full Text] [Related]
14. Chemoenzymatic Synthesis of 9NHAc-GD2 Antigen to Overcome the Hydrolytic Instability of O-Acetylated-GD2 for Anticancer Conjugate Vaccine Development.
Wu X; Ye J; DeLaitsch AT; Rashidijahanabad Z; Lang S; Kakeshpour T; Zhao Y; Ramadan S; Saavedra PV; Yuzbasiyan-Gurkan V; Kavunja H; Cao H; Gildersleeve JC; Huang X
Angew Chem Int Ed Engl; 2021 Nov; 60(45):24179-24188. PubMed ID: 34469031
[TBL] [Abstract][Full Text] [Related]
15. Ganglioside vaccines with emphasis on GM2.
Livingston P
Semin Oncol; 1998 Dec; 25(6):636-45. PubMed ID: 9865678
[TBL] [Abstract][Full Text] [Related]
16. On the emerging role of chemistry in the fashioning of biologics: synthesis of a bidomainal fucosyl GM1-based vaccine for the treatment of small cell lung cancer.
Nagorny P; Kim WH; Wan Q; Lee D; Danishefsky SJ
J Org Chem; 2009 Aug; 74(15):5157-62. PubMed ID: 19555091
[TBL] [Abstract][Full Text] [Related]
17. Induction of antibodies against GM2 ganglioside by immunizing melanoma patients using GM2-keyhole limpet hemocyanin + QS21 vaccine: a dose-response study.
Chapman PB; Morrissey DM; Panageas KS; Hamilton WB; Zhan C; Destro AN; Williams L; Israel RJ; Livingston PO
Clin Cancer Res; 2000 Mar; 6(3):874-9. PubMed ID: 10741710
[TBL] [Abstract][Full Text] [Related]
18. A conjugate of an oligosaccharide fragment of tumor-associated ganglioside antigen with hemocyanin is a prototype antitumor vaccine.
Stepanenko RN; Tsvetkov YE; Khatuntseva EA; L'vov VL; Vlasenko RY; Nifant'ev NE; Petrov RV
Dokl Biol Sci; 2007; 415():298-301. PubMed ID: 17929671
[No Abstract] [Full Text] [Related]
19. Comparison of the effect of different immunological adjuvants on the antibody and T-cell response to immunization with MUC1-KLH and GD3-KLH conjugate cancer vaccines.
Kim SK; Ragupathi G; Musselli C; Choi SJ; Park YS; Livingston PO
Vaccine; 1999 Nov; 18(7-8):597-603. PubMed ID: 10547417
[TBL] [Abstract][Full Text] [Related]
20. Vaccination with a bivalent G(M2) and G(D2) ganglioside conjugate vaccine: a trial comparing doses of G(D2)-keyhole limpet hemocyanin.
Chapman PB; Morrisey D; Panageas KS; Williams L; Lewis JJ; Israel RJ; Hamilton WB; Livingston PO
Clin Cancer Res; 2000 Dec; 6(12):4658-62. PubMed ID: 11156217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]